A clinical case of the use of a combination of cimicoxib and cyclophosphamide in metronomic mode in neoadjuvant therapy of complex breast carcinoma of a dog
DOI:
https://doi.org/10.28983/asj.y2023i5pp85-90Keywords:
cyclooxygenase-2, cimicoxib, cyclophosphamide, mammary gland cancer, dogAbstract
The results of the use of a combination of cimicoxib and cyclophosphamide, in metronomic mode, in neoadjuvant therapy of complex breast carcinoma in dogs are presented. This treatment regimen allowed to achieve stabilization of the process, the volume of the tumor decreased by 60.77% of the indicators of the first day. The regression was 39.23%. According to the results of hematological blood examination, by the 90th day of therapy, the number of leukocytes decreased by 75.96%, lymphocytes by 79.67% and granulocytes by 75.64%, to reference values. The number of red blood cells and the level of hemoglobin increased by 49.57% and 53.98%, respectively. There was an increase in the amount of hematocrit by 52.35% compared to the values of the first day before therapy. Biochemical parameters of blood serum by the end of drug therapy were within the reference values. There were no signs of hematological and general toxicity, according to the WHO scale, requiring corrective therapy, dose reduction or withdrawal of drugs.
Downloads
References
Горинский В. И., Салаутин В. В., Пудовкин Н. А., Салаутина С. Е. Анализ распространения онкологических заболеваний домашних непродуктивных животных в административных районах города Волгограда // Аграрный научный журнал. 2022. № 1. С. 51–54.
Комплексный подход в диагностике новообразований молочной железы у домашних непродуктивных животных / В. И. Горинский [и др.] // Международный вестник ветеринарии. 2022. № 2. С.74–84.
Clinical outcome of dogs diagnosed with canine inflammatory mammary cancer treated with metronomic cyclophosphamide, a cyclooxygenase-2 inhibitor and toceranib phosphate / D. Alonso-Miguel et al. // Vet Comp Oncol. 2022;20(1):179–188.
A Statistical Analysis of Risk Factors and Biological Behavior in Canine Mammary Tumors: A Multicenter Study / G. P. Burrai et al. Animals (Basel). 2020 Sep; 10(9): 1687. Published online 2020 Sep 18. DOI: 10.3390/ani10091687 PMCID: PMC7552647 PMID: 32961915.
Hormonal Homologies between Canine Mammary Cancer and Human Breast Cancer in a Series of Cases / P. J. de Andr?s et al. Vet Sci. 2022Aug;9(8):395. Published online 2022. Jul. 29. DOI: 10.3390/vetsci9080395 PMCID: PMC9414677 PMID: 3600–6309.
Ultrasonographic assessment of renal perfusion in bitches with mammary carcinoma treated with long-term carprofen / С.R.V. Estrada et al. Sci Rep. 2021 Dec 2;11(1):23277. DOI: 10.1038/s41598-021-02781-3 PMID: 34857853 PMCID: PMC8640024.
The role of COX expression in the prognostication of overall survival of canine and feline cancer: A systematic review / H. Greg?rio et al. Vet Med Sci. 2021 Jul;7(4):1107–1119. DOI: 10.1002/vms3.460. Epub 2021 Mar 10. PMID: 33751829 PMCID: PMC8294401.
Hurst E. A., Pang L. Y., Argyle D. J. The selective cyclooxygenase-2 inhibitor mavacoxib (Trocoxil) exerts anti-tumour effects in vitro independent of cyclooxygenase-2 expression levels.Vet Comp Oncol. 2019 Jun; 17(2):194–207.
Kaszak I., Witkowska-Pi?aszewicz O., Domrazek K., Jurka P. The Novel Diagnostic Techniques and Biomarkers of Canine Mammary Tumors. Vet Sci. 2022 Oct; 9(10): 526. Published online 2022 Sep 26. DOI: 10.3390/vetsci9100526
PMCID: PMC9610006 PMID: 36288138.
LncRNA34977 promotes the proliferation, migration, and invasion and inhibits the apoptosis of canine mammary tumors by regulating the expression of miR-8881/ELAVL4 / B. Lu et al. Funct Integr Genomics. 2023;23(1):31. Published online 2023 Jan 6. DOI: 10.1007/s10142-022-00955-4 PMCID: PMC9816241 PMID: 36604379.
Clinical, epidemiological, and histopathological aspects of breast cancer in female dogs at Federal Rural University of Rio de Janeiro Veterinary Hospital / L. C. Oliveira et al. Braz J Vet Med. 2022; 44: e000722. Published online 2022 Sep 16. DOI: 10.29374/2527-2179.bjvm000722 PMCID: PMC9484584 PMID: 36134124.
Oluwafunke R., Khosrow K. NSAIDs and Cancer Resolution: New Paradigms beyond Cyclooxygenase. International Journal of Molecular Sciences. 2022;(23): 14–32. https://doi.org/10.3390/ijms23031432.
Sakalauskait? S., ?altenien? V., Nikitina D., Ugenskien? R., Ri?kevi?ien? V., Karvelien? B., Juod?iukynien? N. VEGF-B, VEGF-A, FLT-1, KDR, ERBB2, EGFR, GRB2, RAC1, CDH1 and HYAL-1 Genes Expression Analysis in Canine Mammary Gland Tumors and the Association with Tumor ClinicoPathological Parameters and Dog Breed Assessment. Vet Sci. 2021 Oct; 8(10): 212. Published online 2021 Sep 30. DOI: 10.3390/vetsci8100212 PMCID: PMC8537314 PMID: 34679042.
Suryawanshi R.V. Assessment of Efficacy and Toxicity of Cyclophosphamide Chemotherapy in Canines with Malignant Mammary Tumor: A Retrospective Study. Vet Med Int. 2021;(12):552–603. DOI: 10.1155/2021/5520603. eCollection 2021. PMID: 34422254 PMCID: PMC8378984.
Valdivia G., Alonso-Diez ?., P?rez-Alenza D., Pe?a L. From Conventional to Precision Therapy in Canine Mammary Cancer: A Comprehensive Review. Front Vet Sci. 2021;8:623–800. Published online 2021. Feb. 17. DOI: 10.3389/fvets.2021.623800 PMCID: PMC7925635 PMID: 33681329.
COX-2 expression in mammary invasive micropapillary carcinoma is associated with prognostic factors and acts as a potential therapeutic target in comparative oncology / T. C. Vieira et al. Front Vet Sci. 2022. Sep 12;9:983110. DOI: 10.3389/fvets.2022.983110. Collection 2022. PMID: 36172611. PMCID: PMC9510711.
Withrow & MacEwen’s. Small Animal Clinical Oncology. 6-TH EDITION. Copyright © 2020 by Elsevier, Inc. Р. 842.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 The Agrarian Scientific Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
